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Purpose: The PAX6 gene, located at the reported myopia locus MYP7 on chromosome 11p13, was postulated to be
associated with myopia development. This study investigated the association of PAX6 with high myopia in 379 high
myopia patients and 349 controls.
Methods: High myopia patients had refractive errors of –6.00 diopters or greater and axial length longer than 26 mm.
Control subjects had refractive errors less than –1.00 diopter and axial length shorter than 24 mm. The P1 promoter, all
coding sequences, and adjacent splice-site regions of the PAX6 gene were screened in all study subjects by polymerase
chain reaction and direct sequencing. PAX6 P1 promoter-luciferase constructs with variable AC and AG repeat lengths
were prepared and transfected into human ARPE-19 cells prior to assaying for their transcriptional activities.
Results: No sequence alterations in the coding or splicing regions showed an association with high myopia. Two
dinucleotide repeats, (AC)m and (AG)n, in the P1 promoter region were found to be highly polymorphic and significantly
associated with high myopia. Higher repeat numbers were observed in high myopia patients for both (AC)m (empirical
p = 0.013) and (AG)n (empirical p = 0.012) dinucleotide polymorphisms, with a 1.327-fold increased risk associated with
the (AG)n repeat (empirical p = 0.016; 95% confidence interval: 1.059–1.663). Luciferase-reporter analysis showed
elevated transcription activity with increasing individual (AC)m and (AG)n and combined (AC)m(AG)n repeat lengths.
Conclusions: Our results revealed an association between high myopia and AC and AG dinucleotide repeat lengths in
the PAX6 P1 promoter, indicating the involvement of PAX6 in the pathogenesis of high myopia.
Myopia, one of the most common refractive errors of the
eye worldwide, is an important public health issue, especially
in Asia, because of its higher prevalence in Asians than in
other populations [1]. The progression of myopia in Chinese
children in Hong Kong and Singapore is also much higher than
in Caucasians [2,3]. In Hong Kong, the prevalence of myopia
in Chinese schoolchildren aged 11–16 was 36.7%, according
to a 2004 report, which is several times higher than among
Caucasian children of similar ages [4]. The prevalence of high
myopia, defined as a refractive error equal to or greater than
–6.00  diopters  (D),  is  also  higher  in  Chinese  than  in
Caucasians  [5,6].  Individuals  with  high  myopia  are  more
prone to develop serious ocular complications, such as retinal
detachment,  glaucoma,  premature  cataracts,  and  macular
degeneration, which may lead to visual impairment or even
blindness [7-10].
Myopia  is  a  complex  disorder.  Multiple  interacting
environmental  and  genetic  causes  are  implicated.  Myopia
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development  in  schoolchildren  has  been  attributed  to
environmental factors, such as near work, reading habits, and
school achievement [3,11,12]. In addition, high heritability of
refractive  errors  has  been  observed  in  dizygotic  and
monozygotic twin studies [13-17]. Family and sibling studies
have  shown  that  children  of  myopic  parents  have  greater
chances of developing myopia than those with nonmyopic
parents [11,18]. Twenty-four chromosomal loci have been
identified for myopia: Xq28 (MYP1) [19], 18p11.31 (MYP2)
[20,21], 12q21-31 (MYP3) [22], 7q36 (MYP4) [23], 17q21-22
(MYP5) [24], 22q37.1 (MYP6) [25], 11p13 (MYP7) [26], 3q26
(MYP8) [26], 4q12 (MYP9) [26], 8p23 (MYP10) [26], 4q22-
q27 (MYP11) [27], 2q37.1 (MYP12) [28], Xq23 (MYP13)
[29], 1p36 (MYP14) [30], 10q21.2 (MYP15) [31], 5p15.33-
p15.2 (MYP16) [32], 7p15 (MYP17) [33,34], 14q22.1-q24.2
(MYP18) [35], 15q12-13 [36], 21q22.3 [37], 12q24 [38], 4q21
[38], 9q34.11 [39] and 2q37 [40]. Among them,  MYP1–5,11–
13,16, and 18 are linked to high myopia, and MYP2,11,13,
16,  and  18  are  found  in  the  Chinese  population.  Some
candidate genes have been postulated for myopia, such as
TGIF [41], HGF [42], MMP3 [43], MMP9 [43], COL1A1
[44], COL2A1 [45], TGFB1 [46], TGFB2 [47], LUM [48], and
CMET [49].
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2239A  genome-wide  scan  in  dizygotic  twins  revealed  a
susceptibility locus for myopia on chromosome 11p13 [26].
The PAX6 gene at this locus, a member of the paired-domain
PAX family, has been postulated as a candidate gene for
myopia. PAX6 is expressed in the human eye [50] and plays
an  evolutionarily  conserved  role  in  ocular  development
[51-53]. PAX6 mutations are associated with ocular disorders,
such as aniridia (OMIM 106210), cataracts (OMIM 604219),
Peters anomaly (OMIM 604229), and optic nerve hypoplasia
(OMIM 16550). PAX6 encodes a transcriptional regulator
containing  the  DNA-binding  paired  domain,  paired-type
homeodomain, and COOH-terminal transactivation domain.
The Pax6 protein regulates cell adhesion molecules, cell-to-
cell signaling molecules, hormones, and structural proteins
[54] through interactions with transcription factors such as
Mitf [55] and Sox2 [56]. Transcription of PAX6 is regulated
by at least two promoters, P0 and P1 [57-60]. Within the P1
promoter  (promoter  B  in  Okladnova  et  al.  [59]),  two
dinucleotide repeats, (AC)m and (AG)n, are located about 1 kb
from  the  transcription  start  site  [58]  and  are  highly
polymorphic in Caucasians. The poly AC and poly AG repeats
are independently polymorphic [60]. Luciferase analysis in
Cos-7 cells has shown that the longer the combined length of
the AC and AG repeats, the higher the transcriptional activity,
implying that the length of this dinucleotide repeat might
influence the transcriptional activity of promoter B, or P1, and
subsequently the transcription of PAX6.
Pax6 levels are tightly controlled. Both overexpression
and haploinsufficiency lead to abnormal phenotypes [61-63].
Polymorphisms or mutations in the PAX6 promoter could
influence PAX6 expressions that ultimately lead to a disease
phenotype. However, although PAX6 has been postulated to
be a candidate gene for myopia, several studies in Caucasian
populations could not find an association between PAX6 and
myopia  [26,45,64].  Still,  an  Australian  study  suggested
PAX6 mutations might be associated with high myopia [65].
Intronic  sequence  alterations  (SNPs)  in  PAX6  have  been
reported to associate with high myopia in Han Chinese nuclear
families [66] and with extreme myopia in a Taiwan Chinese
population  [67],  but  not  in  Caucasians.  To  attest  the
association between PAX6 and high myopia, we should look
for mutations that may affect PAX6 expressions. We therefore
screened for sequence alterations in the P1 promoter, coding
exons, and adjacent splice-site regions of PAX6 in unrelated
high myopia patients and control subjects. We also examined
transcriptional effects of dinucleotide repeats within the P1
promoter in cultured human APRE-19 cells by a luciferase-
reporter  assay  and  predicted  the  presence  of  transcription
factor binding sites within the repeats.
METHODS
Study  subjects:  We  recruited  379  unrelated  Han  Chinese
patients with high myopia at the Hong Kong Eye Hospital.
They were given complete ophthalmoscopic examinations.
None  of  them  had  known  diseases  predisposing  them  to
myopia,  such  as  Stickler  or  Marfan  syndromes.  Their
refractive errors were equal to or greater than –6.00 D, and
their axial length was longer than 26 mm. We also recruited
349  unrelated  Chinese  control  subjects  who  visited  the
hospital  for  ophthalmic  examinations.  They  had  no  eye
diseases except senile cataracts and slight floaters. All of them
had refractive errors of less than –1.00 D and axial length
shorter than 24 mm. The study protocol was approved by the
Ethics  Committee  for  Human  Research  at  the  Chinese
University of Hong Kong and was in accordance with the
tenets of the Declaration of Helsinki. Informed consent was
obtained  from  the  study  subjects  after  explanation  of  the
nature and possible consequences of the study.
Construction of PAX6 P1 promoter-luciferase constructs: A
1,851 bp genomic fragment (from –1278 to +573) containing
the PAX6 P1 promoter was cloned into an empty pGL3-Basic
vector, pGL3 (Promega, Madison, WI) between the SacI and
BglII  sites  (OriGene  Technologies,  Rockville,  MD).
Constructs  with  different  repeat  lengths  were  generated.
Genomic DNA from the study subjects was amplified by PCR
(forward primer 5'-ACA CAC AGA TGA CCG GTG G-3';
reverse primer 5'-AAG CCT AGG CCG AGA GGA-3'). AgeI
and AvrII digested products were ligated into a linearized
pGL3-Basic  vector  containing  the  P1  promoter  (pGL3-
Pax6p). A positive control construct was made by cloning a
pCMV5 promoter [68] into the pGL3-Basic vector (pGL3-
pCMV). All constructs were verified by direct sequencing.
Cell culture and transfection: The human retinal pigment
epithelial  cell  line  ARPE-19  (American  Type  Culture
Collection, Manassas, VA) [69] was cultured in Dulbecco’s
modified  Eagle’s  medium  and  F-12  nutrient  mixture
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PAX6 genotyping: The whole blood specimens (5 ml) from
all the patients and controls were collected in EDTA tube and
stored at -80 °C for fewer than two months. Genomic DNA
was extracted (QIAamp DNA kit; Qiagen, Hiden, Germeny)
according to the supplier’s instructions. All samples were
screened for sequence alterations in the P1 promoter region
flanking  –3,433  to  –118,  coding  exons,  and  intron-exon
boundaries  of  PAX6  (ENSG00000007372  and
ENST00000241001;  Ensembl  genome  browser)  by
polymerase chain reaction (PCR) with primer sets [61]. PCR
was performed in a final volume of 25 μl containing 1X PCR
buffer (Invitrogen™ Life Technology, Carlsbad, CA), 1.5
mM MgCl2, 0.2 mM of dNTP (Roche, Indianapolis, IN), 0.2
mM  of  each  primers,  0.5  U  of  Platinum®  Taq  DNA
polymerase (Invitrogen). After the initial denaturation at 95
°C for 2 min, 40 PCR cycles were conducted: 95 °C for 45 s,
57 °C for 45 s and 72 °C for 45 s. The final extension lasted
for 5 min at 72 °C. Direct sequencing was performed using a
BigDye Terminator Cycle Sequencing Reaction Kit (v3.1,
Applied Biosystems, Foster City, CA) on an ABI 3130XL
capillary DNA sequencer (Applied Biosystems).supplemented  with  10%  fetal  bovine  serum  (Gibco  BRL,
Rockville, MD). Cells were plated in 60 mm tissue culture
dishes  at  a  density  of  2–3×105  cells/dish  one  day  before
transfection. At 60–80% confluence, cells were transfected
with 2 μg luciferase constructs in 6 μl FuGene HD (Roche)
transfection reagent per dish. Empty pGL3 and pGL3-pCMV
were used as negative and positive controls, respectively. At
36 h after transfection, cell lysates were extracted using Cell
Culture  Lysis  Reagent  (Promega,  Madison,  WI)  for
immunoblotting.
Immunoblotting: The denatured cell lysates of the transfected
cells  were  resolved  on  10%  SDS-polyacrylamide  gel  and
electro-transferred to nitrocellulose membranes for probing
with  a  rabbit  polyclonal  primary  antibody  against  firefly
luciferase (Sigma-Aldrich, St. Louis, MO) and a secondary
antibody  against  rabbit  IgG  conjugated  with  horseradish
peroxidase (Jackson Immuno Res., West Grove, PA). The
chemiluminescence  was  detected  by  an  enhanced
chemiluminescence  system  (Amersham  Pharmacia,
Cleveland,  OH)  and  quantified  by  ChemiDoc  (BioRad,
Hercules,  CA).  Normalized  luciferase  intensities  were
calculated by dividing the quantified luciferase intensities by
the  housekeeping  β-actin  intensities.  Triplicates  were
performed.
Statistical analysis: The χ2 test or Fisher exact test was used
to compare the allele and genotype frequencies of SNPs in
patients and control subjects. For the comparison of (AC)m
and (AG)n repeat alleles and genotypes between high myopia
patients and control subjects, the χ2 test was performed using
the CLUMP program (version 2.3) [70]. For multiple testing
corrections, 10,000 Monte Carlo permutations were chosen to
simulate  the  empirical  significance  levels  of  the  statistics
produced by the program, resulting in an empirical p-value.
Due  to  low  frequencies  of  some  alleles,  and  in  order  to
determine whether the transcriptional activities were affected
by the thresholds, (AC)m and (AG)n repeats were collapsed
into groups for association study and immunoblotting analysis
[71,72]. The risk of high myopia was also determined by odds
ratio using the χ2 test. Activity of each allelic construct was
expressed relative to (AC)20(AG)6. One-way ANOVA and
independent T-testing were used to compare the means among
(AC)m groups and between (AG)n repeats, respectively. SNP-
trait association, odds ratio calculation, and immunoblotting
analysis  were  performed  on  SPSS  version  16.0  (SPSS
Science, Chicago, IL). Significance was defined as p < 0.05.
Transcription  factor  binding  site  prediction:  The  DNA
sequence of the cloned PAX6 P1 promoter was used to predict
transcription factor binding sites. The Transcription Element
Search  System  (TESS:  University  of  Pennsylvania,
Philadelphia, PA) [73,74] was used to predict the transcription
factors  that  would  bind  to  the  region  of  the  dinucleotide
repeats in the PAX6 P1 promoter. Predictions for different
lengths of dinucleotide repeats were also performed. As in the
statistical analysis for immunoblotting, (AC)20(AG)6 was set
Within the PAX6 P1 promoter, two dinucleotide repeats,
(AC)m  and  (AG)n,  were  observed  about  1  kb  from  the
transcription start site, both highly polymorphic (Table 1).
The AC repeats ranged from 16 to 26 in high myopia patients
and from 7 to 26 in control subjects, while 5 to 8 AG repeats
were observed in patients and 4 to 8 in controls. The median
numbers of AC and AG repeats were 20 and 6, respectively,
in  both  patients  and  controls.  Distribution  of  the  allele
frequencies was slightly skewed in patients for both AC and
AG repeats. Allele frequencies of the AC and AG repeats were
significantly  different  between  patients  and  controls
(empirical  p  =  0.013  and  0.012,  respectively;  Table  1).
Because the frequencies of some of the alleles were low, the
AC and AG repeats were collapsed into groups. The grouped
repeat  lengths  were  longer  in  patients  than  in  controls
(empirical p = 0.016 for (AC)m and empirical p = 0.016 for
(AG)n; Table 2). In terms of risk analysis, individuals with
(AG)7-8 repeats had a 1.327-fold increased risk of developing
high myopia compared with the those with (AG)4-6 repeats
(empirical  p  =  0.016;  95%  confidence  interval  =  1.059–
1.663). Both grouped AC and grouped AG genotypes were
significantly  different  between  high  myopia  patients  and
control (empirical p = 0.004 and 0.039, respectively; Table 3).
We  found  that  the  dinucleotide  repeats  affected  the
transcriptional activity of the PAX6 P1 promoter (Figure 1).
For  a  given  (AG)n  repeat  length,  elevated  transcriptional
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RESULTS
In our study cohort, high myopia patients had a mean age of
39.52±14.96  years  and  a  male-to-female  ratio  of  1.2:1.
Refractive errors ranged from –6.00 to –30.00 D. For the
controls, the mean age was 64.85±14.85 years, with a male-
to-female ratio of 1.6:1. There was no significant difference
in the sex ratio between high myopia patients and controls.
Two sequence changes were identified in coding exons
with  the  intron-exon  boundary  of  PAX6.  One  novel
heterozygous silent variant, 678A>G (R67R), was found in
one high myopia patient, and a noncoding sequence change,
rs667773, was found in both patients and controls. Allelic and
genotypic  frequencies  of  both  polymorphisms  showed  no
significant difference (p > 0.05) between patients and controls
(data  not  shown).  Within  the  P1  promoter  region,  20
polymorphisms were identified, with no significant difference
in frequencies between patients and controls: –186C>T, –
215G>A,  –242G>A,  –263A>G,  –292A>G,  –331A>G,  –
337A>T,  –354A>G,  –382G>A,  –407G>A,  –409G>A,  –
692A>G,  –758C>T,  –782A>G,  –933C>G,  –3050C>A,  –
3070C>A, –3078A>G, –3090C>T, and –3282T>C (data not
shown). For -186C>T, -292A>G, -331A>G, -933C>G, and
-3282T>C, each SNP was only found in 1 high myopia patient.
Therefore,  they  were  statistically  not  significant  under
Pearson’s χ2 test (p > 0.05).activity was observed with increasing length of (AC)m repeats
(p = 0.004, one-way ANOVA; post-hoc tests adjusted by
Tukey HSD: (AC)Below20–22 versus (AC)20–22, p = 0.033; and
(AC)Below20–22 versus (AC)Above20–22, p = 0.004; Figure 1A,B).
Similarly,  at  a  given  (AC)m  repeat  length,  transcriptional
activity of (AG)8 was increased when compared with (AG)6,
although the increase was not significant, likely due to the
substantial standard deviation (p = 0.205, independent T-test;
Figure  1C,D).  For  combined  repeats  of  the  same  length,
transcriptional activity of (AC)23(AG)6 was similar to that of
(AC)21(AG)8 (p = 0.627, independent T-test; Figure 1E,F).
Thus,  both  AC  and  AG  repeats  contributed  to  the
transcriptional activity of the PAX6 P1 promoter.
Our  luciferase-reporter  analysis  showed  that
transcription activity increased with AC and AG repeat length.
This phenomenon may be due to influences of transcription
factor  binding  sites  within  this  region.  Thus,  we  used
(AC)20(AG)6 as a reference and predicted one binding site for
T-cell factor/Lymphoid enhancer factor family transcription
factors, one glucocorticoid receptor binding site, and four
transcription factor (TF) II-I binding sites (Figure 2B). With
decreasing AG repeat lengths, the T-cell factor/Lymphoid
enhancer  factor  and  glucocorticoid  receptor  sites  were
unchanged,  but  the  TFII-I  sites  were  reduced.  Only  two
predicted TFII-I sites were observed in (AC)15(AG)4 (Figure
2A). No alteration was observed with a decrease in AC repeat
TABLE 1. ALLELIC FREQUENCIES OF PAX6 P1 PROMOTER DINUCLEOTIDE REPEATS IN HIGH MYOPIA (HM) AND CONTROL SUBJECTS.
(AC)m repeat
Allelic count (%) Empirical
  p-value (AG)n repeat
Allelic count (%) Empirical
  p-value HM n=750            Control n=678                                                                   HM n=758            Control n=698
(AC)7 0 (0.0) 1 (0.1) 0.013 (AG)4 0 (0.0) 1 (0.1) 0.012
(AC)15 0 (0.0) 2 (0.3) (AG)5 45 (5.9)                      51 (7.3)
(AC)16 10 (1.3) 9 (1.3) (AG)6 464 (61.2)                  458 (65.6)
(AC)17 43 (5.7) 41 (6.0)                                               (AG)7 218 (28.8)                  176 (25.2)
(AC)18 80 (10.7) 67 (9.9)                                               (AG)8 31 (4.1)                      12 (1.7)
(AC)19 100 (13.3) 138 (20.4)
(AC)20 155 (20.7) 134 (19.8)
(AC)21 149 (19.9) 99 (14.6)
(AC)22 161 (21.5) 138 (20.4)
(AC)23 29 (3.9) 33 (4.9)
(AC)24 13 (1.7) 13 (1.9)
(AC)25 6 (0.8) 2 (0.3)
(AC)26 4 (0.5) 1 (0.1)
TABLE 2. ALLELIC FREQUENCIES OF PAX6 P1 PROMOTER GROUPED DINUCLEOTIDE REPEATS, (AC)m AND (AG)n, IN HIGH MYOPIA (HM) AND CONTROL SUBJECTS.
Grouped 
(AC) m repeat
Allelic count (%) Empirical 
p-value
Grouped
(AG)n repeat
Allelic count (%) Empirical 
p-value HM n=750             Control n=678                                                                   HM n=758            Control n=698
(AC)Below 20-22 233 (31.1) 258 (38.1) 0.016 (AG)4-6 509 (67.2) 510 (73.1) 0.016
(AC)20-22 465 (62.0) 371 (54.7)                                              (AG)7-8 249 (32.8)                 188 (26.9)
(AC)Above 20-22 52 (6.9) 49 (7.2)
TABLE 3. GENOTYPIC FREQUENCIES OF PAX6 P1 PROMOTER GROUPED DINUCLEOTIDE REPEATS IN HIGH MYOPIA (HM) AND CONTROL SUBJECTS.
Grouped
  (AC)m
genotype
Genotypic count (%) Empirical 
p-value
Grouped
(AG)n
genotype
Genotypic count (%) Empirical 
p-value HM n=375              Control n=339                                                                             HM n=379                 Control n=349
(AC)Below 20-22 /
(AC)Below 20-22
16 (4.3%) 40 (11.8%) 0.004 (AG)4-6 /
(AG)
173 (45.6%) 192 (55.0%) 0.039
(AC)Below 20-22 /
(AC)20-22
178 (47.5%) 149 (44.0%)                                                (AG)4-6 /
(AG)7-8
163 (43.0%)                  126 (36.1%)
(AC)Below 20-22 /
(AC)Above 20-22
24 (6.4%) 29 (8.6%)                                                 (AG)7-8 /
(AG)7-8
43 (11.3%)                     31 (8.9%)
(AC)20-22 / (AC)20-22 130 (34.7%) 103 (34.7%)
(AC)20-22 / (AC)Above
20-22
26 (6.9%) 16 (4.7%)
(AC)Above 20-22 /
(AC)Above 20-22
1 (0.3%) 2 (0.6%)
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4-6lengths. Accordingly, more TFII-I sites were predicted with
increasing AG repeat lengths. Multiple sites for Wilms’ tumor
transcription factor without lysine-threonine-serine [Wt1(–
KTS)] were observed with an increase in AC repeat length,
and one GAGA factor binding site appeared with an increase
in AG repeat length. In (AC)26(AG)8, six TFII-I sites, six
Wt1(–KTS) sites, and one GAGA factor site were predicted
(Figure 2C).
DISCUSSION
We found no myopia mutations in the coding regions and
splice sites in PAX6 in our cohort of Chinese high myopia
patients. Some SNPs were detected in the P1 promoter, exon
7, and intron 10, but these were not statistically significant
(data  not  shown).  In  a  recent  report,  two  intronic  SNPs
(rs3026390  and  rs3026393,  located  in  introns  12  and  13,
respectively) have been shown to be associated with high
myopia  in  Han  Chinese  nuclear  families  [66].  SNP
rs667773,  located  in  intron  10,  is  in  the  same  linkage
disequilibrium block with rs3026390 and rs3026393 [66].
However, in our study, no significant association was found
for  rs667773  between  high  myopia  patients  and  controls,
which was consistent with a previous case-control association
study in a Taiwan Chinese population [67]. The discrepancy
might be due to the much lower minor allele frequency of
rs667773 (0.137) than of rs3026390 and rs3026393 (0.472
and 0.493, respectively) [66]. Other studies have suggested
that rs667773, as a neural polymorphism, is an unlikely cause
of overt phenotypes such as aniridia [75,76].
The (AC)m(AG)n dinucleotide repeat sequence, located
about 1 kb from the transcription start site of the PAX6 P1
promoter,  is  highly  polymorphic.  The  AC  dinucleotide
polymorphism ranged from 18 to 31 repeats and AG ranged
from 5 to 7 repeats in a Caucasian population [60]. In our
Chinese cohort, the AC repeats ranged from 7 to 26 and the
AG repeats from 4 to 8 (Table 1). The allele size of the AG
repeats was similar in Caucasians and Chinese, but the AC
repeat length was longer in Caucasians. Notably, one (AC)7
allele was found in a control subject, far from the common
range of repeats between 15 and 26. In addition, many of the
dinucleotide repeats were heterozygous in both poly AC and
poly  AG  repeats  (AC:  55.3%  in  controls  and  75.9%  in
patients; AG: 42.9% in controls and 53.4% in patients). The
observed  heterozygosity  rate  was  65%  in  a  Caucasian
population [60]. Although the allele number in that study was
defined as combined units of AC and AG repeats instead of
independent AC and AG alleles, the trend of heterozygosity
was similar to that in our work. These two dinucleotide repeats
Figure  1.  Transcriptional  activity  of
dinucleotide  repeats  in  the  PAX6  P1
promoter. A 1,851 bp genomic fragment
(from  –1278  to  +573)  containing  the
PAX6  P1  promoter  with  different
dinucleotide repeats was cloned into an
empty pGL3-Basic vector (pGL3) and
transfected  into  ARPE-19  cells.  The
activity  of  each  allelic  construct  is
expressed  relative  to  the  construct
(AC)20(AG)6.  Data  are  represented  as
mean±SD  for  five  independent
experiments. A and B: Immunoblotting
results  and  a  bar  chart  show  relative
luciferase  activity  for  grouped  (AC)m
repeats with a stable (AG)6. C and D:
Immunoblotting results and a bar chart
show  relative  luciferase  activity  for
(AG)   repeats with (AC)   .  E and F:
Immunoblotting results and a bar chart
show  relative  luciferase  activity  for
combined (AC)   (AG)   repeats.
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m nare, therefore, highly polymorphic both in Caucasians and in
Chinese.
The PAX6 P1, containing CCAAT boxes and a TATA-
like box, is likely a real promoter [58-60]. We evaluated the
influence of (AC)m(AG)n dinucleotide repeats on PAX6 P1
promoter activity by a luciferase-reporter assay and examined
the effects of repeat lengths as obtained from our high myopia
patients and controls. Since retinal pigment epithelium (RPE)
has been shown to have PAX6 P1 promoter activity [57], we
used  an  RPE  cell  line,  ARPE-19,  for  transfection.
Immunoblotting showed that longer lengths of (AC)m have a
significant trend of increasing luciferase expression compared
with shorter lengths (Figure 1A,B), although this was not
observed for (AG)n, likely due to the substantial standard
deviation (Figure 1C,D).
We  confirmed  that  transcriptional  activity  of
(AC)23(AG)6 was similar to that of (AC)21(AG)8 (Figure 1E,F),
suggesting that both (AC)m and (AG)n dinucleotide repeats
within the PAX6 P1 promoter contribute to transcriptional
activity and might work cooperatively as an unit. Previous
studies on luciferase-reporter assays assessed the promoter
activity invisibly by a luminometer [60,77]. In our study, we
monitored the luciferase-reporter assay by immunoblotting
using  a  commercially  available  antibody  against  firefly
luciferase and luciferase overexpression by pGL3-pCMV as
a  positive  control.  There  are  technical  advantages  to  this
method. The promoter activity could be visualized, and co-
transfection with another normalizing vector was not required,
as the luciferase intensity could be directly normalized with
the  housekeeping  protein,  assuming  the  same  transfection
efficiency  among  the  constructs.  The  limitation  of  the
luciferase-reporter assay is that the effect of the dinucleotide
repeats on the transcriptional activity was performed using
RPE cells from normal controls, which might not truly reflect
the  situation  in  high  myopia  unless  the  experiment  were
performed using cells from a highly myopic individual.
Since levels of Pax6 are tightly controlled, small and
seemingly insignificant changes in the levels of Pax6 may lead
to significant phenotypic consequences [78]. Moreover, the
Pax6 protein could upregulate PAX6 P1 promoter activity
Figure 2. Transcription factor binding
site prediction for dinucleotide repeats
in the PAX6 P1 promoter. The cloned
PAX6 P1 promoter DNA sequence was
used  to  predict  transcription  factor
binding  sites.  Predicted  transcription
factor binding sites around the region of
the dinucleotide repeats are shown, and
different lengths of AC and AG repeats
are assessed. As in the immunoblotting
analysis,  [(AC)20(AG)6]  was  set  as  a
reference.  A:  Predicted  transcription
factor binding sites for (AC)     (AG)
are  shown.  B:  Predicted  transcription
factor binding sites for (AC)    (AG)
are  shown.  C:  Predicted  transcription
factor binding sites for (AC)    (AG)
are shown.
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26 8[77]. Results of our genotyping and promoter activity analyses
indicate that longer lengths of dinucleotide repeats increase
the expression of PAX6, which increases the risk of high
myopia.  This  postulation  may  be  supported  by  several
assertions: (1) PAX6 gene expression has been shown to be
significantly higher in the retinas of optical defocused eyes
than in contralateral eyes in the rhesus monkey [79], and
expression of PAX6 was also increased in posthatch chicken
eyes with form-deprivation myopia [78]. (2) In another study,
the  number  of  dividing  retinal  progenitor  cells,  of  which
PAX6 is a marker, was highly correlated with axial elongation
of the eye, resulting in myopic refractive errors in primates
with form-deprivation myopia [80]. (3) Pax6 has been shown
to transactivate insulin promoters [81] and promote proinsulin
processing [82]. As insulin is a strong stimulator of axial
myopia  in  chicks  [83],  elevated  PAX6  expression  may
increase the risk of developing myopia through increased
expression  of  insulin.  Chronic  hyperinsulinemia  has  been
proposed as a key player in the pathogenesis of juvenile-onset
myopia [84]. Although Pax6 also transactivates the glucagon
promoter [81], which is a “stop” for myopia [85], insulin
might overcome the effects of glucagon in the development
of myopia [86].
The transcription factor binding site prediction (Figure 2)
showed that an increase in AC repeat length created additional
Wt1(–KTS) binding sites, while an increase in AG repeat
length created TFII-I and GAGA factor binding sites. If the
AG repeat length was reduced, TFII-I sites were also reduced.
Wt1(–KTS) is necessary for normal retina formation in mice
[87],  while  TFII-I  is  a  signal-induced  multifunctional
transcription factor that plays a key role in the regulation of
cell  proliferation  [88].  Moreover,  the  GAGA  factor,  a
transcription  activator,  is  activated  by  epidermal  growth
factors,  platelet-derived  growth  factors,  and  insulin  [89].
These  growth  factors  could  regulate  PAX6  transcription
through the GAGA factor binding site.
In  summary,  we  found  no  association  between
polymorphisms in the PAX6 coding region and high myopia
in our Hong Kong Chinese cohort. Two dinucleotide repeats,
AC and AG, in the PAX6 P1 promoter were associated with
high myopia. These two repeats were also associated with the
elevation of PAX6 P1 promoter activity, and hence an increase
in the transcriptional activity of PAX6. Our results provide
evidence for the role of PAX6 in the pathogenesis of high
myopia.
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